title: Mitral heart disease due to cabergoline.
abstract: The case of a restrictive valve disease associated with cabergoline, an ergot alkaloid agonist used in the treatment of Parkinson's disease, is described. Cardiovascular and periodical follow-up assessment may be required when these drugs are prescribed.
authors.forename: Maria
authors.initials: M
authors.lastname: Martin
authors.forename: Gustavo
authors.initials: G
authors.lastname: Iglesias-Cubero
authors.forename: Beatriz
authors.initials: B
authors.lastname: Diaz Molina
authors.forename: Cesar
authors.initials: C
authors.lastname: Moris De la Tassa
mesh_terms: D000978:Antiparkinson Agents / Q000009:adverse effects*; D000077465:Cabergoline; D004873:Ergolines / Q000009:adverse effects*; D005260:Female; D006349:Heart Valve Diseases / Q000139:chemically induced*; D006801:Humans; D008875:Middle Aged; D008944:Mitral Valve Insufficiency / Q000139:chemically induced*
chemical_list: D000978:Antiparkinson Agents; D004873:Ergolines; D000077465:Cabergoline